Ionis Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell IONS and other ETFs, options, and stocks.

About IONS

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company was founded by Stanley T. 

CEO
Brett P. Monia
CEOBrett P. Monia
Employees
1,402
Employees1,402
Headquarters
Carlsbad, California
HeadquartersCarlsbad, California
Founded
1989
Founded1989
Employees
1,402
Employees1,402

IONS Key Statistics

Market cap
12.49B
Market cap12.49B
Price-Earnings ratio
-35.95
Price-Earnings ratio-35.95
Dividend yield
Dividend yield
Average volume
1.78M
Average volume1.78M
High today
$76.80
High today$76.80
Low today
$75.00
Low today$75.00
Open price
$75.71
Open price$75.71
Volume
1.53M
Volume1.53M
52 Week high
$86.74
52 Week high$86.74
52 Week low
$32.00
52 Week low$32.00

Stock Snapshot

Ionis Pharmaceuticals(IONS) stock is priced at $75.56, giving the company a market capitalization of 12.49B. It carries a P/E multiple of -35.95.

As of 2026-05-24, Ionis Pharmaceuticals(IONS) stock has fluctuated between $75.00 and $76.80. The current price stands at $75.56, placing the stock +0.7% above today's low and -1.6% off the high.

Ionis Pharmaceuticals(IONS) shares are trading with a volume of 1.53M, against a daily average of 1.78M.

During the past year, Ionis Pharmaceuticals(IONS) stock moved between $32.00 at its lowest and $86.74 at its peak.

During the past year, Ionis Pharmaceuticals(IONS) stock moved between $32.00 at its lowest and $86.74 at its peak.

IONS News

Investing.com 1d
Ionis Pharmaceuticals’ SWOT analysis: stock gains momentum on FDA approval - Investing.com

...

Ionis Pharmaceuticals’ SWOT analysis: stock gains momentum on FDA approval - Investing.com
Simply Wall St 5d
Ionis Rises As Diranersen Phase 2 Spurs Biogen Registrational Plans

Biogen and Ionis reported topline Phase 2 CELIA data for diranersen in early Alzheimer's disease, showing robust biomarker and cognitive effects. The antisense...

Ionis Rises As Diranersen Phase 2 Spurs Biogen Registrational Plans
TipRanks 6d
Ionis Pharmaceuticals initiated with a Buy, named a top pick at Citi

Citi initiated coverage of Ionis Pharmaceuticals (IONS) with a Buy rating and $115 price target and named it a top pick among small-to-mid cap biotech stocks. T...

Analyst ratings

88%

of 26 ratings
Buy
88.5%
Hold
11.5%
Sell
0%

People also own

Based on the portfolios of people who own IONS. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.